<SEC-DOCUMENT>0001640334-19-000661.txt : 20190419
<SEC-HEADER>0001640334-19-000661.hdr.sgml : 20190419
<ACCEPTANCE-DATETIME>20190419172630
ACCESSION NUMBER:		0001640334-19-000661
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20190417
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190419
DATE AS OF CHANGE:		20190419

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inmune Bio, Inc.
		CENTRAL INDEX KEY:			0001711754
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				475205835
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38793
		FILM NUMBER:		19758323

	BUSINESS ADDRESS:	
		STREET 1:		1224 PROSPECT STREET
		STREET 2:		SUITE 150
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		8589643720

	MAIL ADDRESS:	
		STREET 1:		1224 PROSPECT STREET
		STREET 2:		SUITE 150
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>inmb_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html><head><title>inmb_8k.htm</title><!--Document Created by EDGARMaster--></head><BODY spellcheck="true" style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px"> <table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td> <div style="HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px" name="hrule"></div> <div style="HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000" name="hrule"></div></td></tr></table></p> <p style="MARGIN: 0px" align="center">&nbsp; </p> <p style="MARGIN: 0px" align="center"><b><font size="3">UNITED STATES</font></b></p> <p style="MARGIN: 0px" align="center"><b><font size="3">SECURITIES AND EXCHANGE COMMISSION</font></b></p> <p style="MARGIN: 0px" align="center"><b><font size="3">Washington, D.C. 20549</font></b></p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b><font size="5">FORM 8-K</font></b></p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b>CURRENT REPORT</b></p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="center">Date of Report (Date of earliest event reported): <b><b>April 19, 2019 (April 17, 2019)</b></b></p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <div align="center"> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="55%" align="center" border="0"> <tr height="15"> <td style="BORDER-BOTTOM: 1px solid" valign="top"> <p style="MARGIN: 0px" align="center"><b><font size="5">INMUNE BIO INC.</font></b></p></td></tr> <tr height="15"> <td> <p style="MARGIN: 0px" align="center">(Exact name of registrant as specified in charter)</p></td></tr></table></div> <p style="MARGIN: 0px" align="center">&nbsp;</p> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="85%" align="center" border="0"> <tr height="15"> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="30%"> <p style="MARGIN: 0px" align="center"><b>Nevada</b></p></td> <td valign="top" width="5%"> <p style="MARGIN: 0px" align="center">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="30%"> <p style="MARGIN: 0px" align="center"><b>001-38793</b></p></td> <td valign="top" width="5%"> <p style="MARGIN: 0px" align="center">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="30%"> <p style="MARGIN: 0px" align="center"><b>47-5205835</b></p></td></tr> <tr height="15"> <td valign="top"> <p style="MARGIN: 0px" align="center">(State or other jurisdiction</p></td> <td valign="top"> <p style="MARGIN: 0px" align="center">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="center">(Commission</p></td> <td valign="top"> <p style="MARGIN: 0px" align="center">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="center">(IRS Employer</p></td></tr> <tr height="15"> <td valign="top"> <p style="MARGIN: 0px" align="center">of incorporation)</p></td> <td valign="top"> <p style="MARGIN: 0px" align="center">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="center">File Number)</p></td> <td valign="top"> <p style="MARGIN: 0px" align="center">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="center">Identification No.)</p></td></tr></table> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b><u>1224 Prospect Street, Suite 150, La Jolla, CA 92037</u></b></p> <p style="MARGIN: 0px" align="center">(Address of Principal Executive Offices) (Zip Code)</p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b><u>(858) 964 3720</u></b></p> <p style="MARGIN: 0px" align="center">(Registrant&#8217;s Telephone Number, Including Area Code)</p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b><u>Not Applicable</u></b></p> <p style="MARGIN: 0px" align="center">(Former Name or Former Address, If Changed Since Last Report)</p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<u>see</u>&nbsp;General Instruction A.2. below):</p> <p style="MARGIN: 0px">&nbsp;</p> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr height="15"> <td width="4%"> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top" width="4%"> <p style="MARGIN: 0px" align="justify"><font face="Wingdings">&#168;</font></p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr> <tr height="15"> <td> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify"><font face="Wingdings">&#168;</font></p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr> <tr height="15"> <td> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify"><font face="Wingdings">&#168;</font></p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr> <tr height="15"> <td> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify"><font face="Wingdings">&#168;</font></p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">Emerging growth company&nbsp;<font face="Wingdings">x</font></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;<font face="Wingdings">&#168;</font></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify"> <table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td> <div style="HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px" name="hrule"></div> <div style="HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000" name="hrule"></div></td></tr></table></p> <p style="MARGIN: 0px"> <table class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr> <tr> <td> <div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr></table></p> <p style="MARGIN: 0px" align="justify"><b>Item 8.01 Other Events </b></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">On April 17, 2019, INmune Bio, Inc. (the &#8220;Company&#8221;) issued a press release (the &#8220;Release&#8221;) announcing that Christopher Baum, Ph.D., Director of Neuroscience and Translational Medicine, presented a poster addressing the Phase 1b trial on the Company&#8217;s drug candidate XPro1595 at the Neuroimmunology Drug Development Summit in Boston on April 17, 2019. </p> <p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p> <p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">A copy of the Release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. Exhibits 99.1 shall not be deemed &#8220;filed&#8221; for purposed of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act. </p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify"><b>Item 9.01 Financial statements and Exhibits</b></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">(d) Exhibits.</p> <p style="MARGIN: 0px">&nbsp;</p> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr height="15"> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="8%"> <p style="MARGIN: 0px" align="justify"><b>Exhibit</b></p> <p style="MARGIN: 0px" align="justify"><b>Number</b></p></td> <td valign="top" width="2%"> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid" valign="bottom"> <p style="MARGIN: 0px" align="justify"><b>Description</b></p></td></tr> <tr height="15" bgcolor="#cceeff"> <td valign="top"> <p style="MARGIN: 0px" align="justify"><a href="inmb_ex991.htm">99.1</a></p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify"><a href="inmb_ex991.htm">Summit Presentation Press Release dated April 17, 2019</a></p></td></tr></table> <p style="MARGIN: 0px" align="left">&nbsp;</p> <p style="MARGIN: 0px" align="left"> <table id="pagebreak23b91522-3419-48ef-ae93-a0ae20cada63" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid">&nbsp;</td></tr> <tr> <td> <div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr></table></p> <p style="MARGIN: 0px">&nbsp;&nbsp;</p> <p style="MARGIN: 0px" align="center"><b>SIGNATURE</b></p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p> <p style="MARGIN: 0px">&nbsp;</p> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr height="15"> <td valign="top"> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top" colspan="2"> <p style="MARGIN: 0px" align="justify"><b>INMUNE BIO INC.</b></p></td> <td></td></tr> <tr height="15"> <td valign="top"></td> <td valign="top" colspan="2"></td> <td> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr> <tr height="15"> <td valign="top" width="50%"> <p style="MARGIN: 0px" align="justify">Date: April 19, 2019</p></td> <td valign="top" width="3%"> <p style="MARGIN: 0px" align="justify">By:</p></td> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="35%"> <p style="MARGIN: 0px" align="justify"><i>/s/ David Moss</i></p></td> <td width="12%"></td></tr> <tr height="15"> <td valign="top"></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">David Moss</p></td> <td></td></tr> <tr height="15"> <td valign="top"></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">Chief Financial Officer</p></td> <td></td></tr></table> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px" align="justify"> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="1" cellpadding="0" width="100%" align="center" border="0"> <tr> <td style="BORDER-BOTTOM: black 1px solid"> <p style="MARGIN: 0px" align="center">&nbsp;</p></td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p></BODY><!--Document Created by EDGARMaster--></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>inmb_ex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head><title>inmb_ex991.htm</title><!--Document Created by EDGARMaster--></head><BODY spellcheck="true" style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px" align="right"><b>EXHIBIT 99.1</b></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b><font size="3">INmune Bio Presenting Poster at the Neuroimmunology Drug Development Summit</font></b></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="justify">LA JOLLA, Calif., April 17, 2019 (GLOBE NEWSWIRE) --&nbsp;INmune Bio, Inc.&nbsp;(NASDAQ:&nbsp;INMB), an immunology company focused on developing treatments that harness the patient&#8217;s innate immune system to fight disease, today announced that Christopher Barnum, Ph.D., Director of Neuroscience and Translational Medicine, will be presenting a poster at the&nbsp;Neuroimmunology Drug Development Summit&nbsp;in Boston on April 17. The poster will address the Phase 1b trial on the company&#8217;s drug candidate XPro1595 for patients with mild to moderate Alzheimer&#8217;s disease.</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="justify">&#8221;Because of our focus on neuroinflammation as a cause of neurologic disease, we have designed a Phase 1 trial that measures traditional and novel biomarkers of inflammation as a first step in our Alzheimer&#8217;s disease program,&#8221; said Dr. Barnum. &#8220;We are looking forward to sharing our ideas with the neurology drug development experts at the conference.&#8221;</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="justify">The poster presentation is titled &#8220;Phase 1b open-label, biomarker-directed study of the brain penetrant, soluble selective inhibitor of soluble tumor necrosis factor (TNF) XPro1595 in patients with mild to moderate Alzheimer&#8217;s disease.&#8221; XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. The poster describes the clinical trial, addressing the inclusion criteria, biomarker strategy and end-points, as well as the way XPro1595 targets soluble TNF.</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="justify">The Neuroimmunology Drug Development Summit brings together neuroimmunology and neuroinflammation experts from the field&#8217;s most active and innovative pharmaceutical and biotech companies.</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><b>About XPro1595</b> XPro2595 is a novel biologic DN-TNF therapy that targets soluble tumor necrosis factor (TNF) without affecting transmembrane TNF.&nbsp; XPro1595 is entering a biomarker-directed Phase 1 clinical trial in patients with mild-to-moderate Alzheimer&#8217;s disease who have neuroinflammation.&nbsp; The trial is supported by a $1 million Part-the-Cloud grant from the Alzheimer&#8217;s Association.&nbsp;</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify"> <table id="pagebreakb52a949c-5bdc-4d04-b6df-c4e1627c6db7" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid">&nbsp;</td></tr> <tr> <td> <div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><b>About INmune Bio, Inc.</b> INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient&#8217;s innate immune system&#8217;s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer&#8217;s disease. INKmune is a natural killer (NK) cell therapeutic that primes the patient&#8217;s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio&#8217;s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit&nbsp;www.inmunebio.com.</p> <p style="MARGIN: 0px">&nbsp;&nbsp;&nbsp;</p><b>INmune Bio Contact:&nbsp;</b> <p style="MARGIN: 0px">David Moss, CFO</p> <p style="MARGIN: 0px">(858) 964-3720</p>DMoss@INmuneBio.com <p style="MARGIN: 0px">&nbsp;</p><b>Media Contact:</b> <p style="MARGIN: 0px">Antenna Group</p> <p style="MARGIN: 0px">Sharon Golubchik</p> <p style="MARGIN: 0px">(201) 465-8008</p>INmuneBio@AntennaGroup.com <p style="MARGIN: 0px">&nbsp;</p><b>Investor Contact:&nbsp;</b> <p style="MARGIN: 0px">KCSA Strategic Communications</p> <p style="MARGIN: 0px">Valter Pinto / Scott Eckstein&nbsp;</p> <p style="MARGIN: 0px">PH: (212) 896-1254 / (212) 896-1210</p>INmune@KCSA.com <p style="MARGIN: 0px">&nbsp;&nbsp;</p> <p style="MARGIN: 0px"> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="1" cellpadding="0" width="100%" align="center" border="0"> <tr> <td style="BORDER-BOTTOM: black 1px solid"> <p style="MARGIN: 0px" align="center">&nbsp;</p></td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p></BODY><!--Document Created by EDGARMaster--></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
